FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

BU Sevin

Research Profile

Anatomy

Tumor Cells, Cultured

Disorders

Chemicals & Drugs

Procedures

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Anne O'Meara Rodriguez; BU Sevin
Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
Anne O'Meara Rodriguez; BU Sevin
In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
MF Janicek; Roberto Angioli; A D Unal; BU Sevin; M Madrigal; RE Estape; Hervy E Averette
p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of BU Sevin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2001: Anne O'Meara Rodriguez; BU Sevin
Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
Gynecologic oncology 2001;83(2):334-42.
1999: Anne O'Meara Rodriguez; BU Sevin
In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
Gynecologic oncology 1999;72(2):143-7.
1997: MF Janicek; Roberto Angioli; A D Unal; BU Sevin; M Madrigal; RE Estape; Hervy E Averette
p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Gynecologic oncology 1997;66(1):94-102.
1997: BU Sevin; JP Perras
Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
American journal of obstetrics and gynecology 1997;176(4):759-66; discussion 766-8.
1997: Paul Braunschweiger; V S Basrur; D Cameron; L Sharpe; O Santos; JP Perras; BU Sevin; Arnold Markoe
Modulation of cisPlatin cytotoxicity by interleukin-1 alpha and resident tumor macrophages.
Biotherapy (Dordrecht, Netherlands) 1997;10(2):129-37.
1997: M Madrigal; MF Janicek; BU Sevin; JP Perras; RE Estape; M Peñalver; Hervy E Averette
In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
Gynecologic oncology 1997;64(1):18-25.
1996: S L Buckley; D M Tritz; Linda Van Le; R Higgins; BU Sevin; Frederick R Ueland; Paul D DePriest; Holly H Gallion; C L Bailey; Richard J Kryscio; Wesley C Fowler; Hervy E Averette; John R van Nagell
Lymph node metastases and prognosis in patients with stage IA2 cervical cancer.
Gynecologic oncology 1996;63(1):4-9.
1996: BU Sevin; M W Method; Mehrdad Nadji; Y Lu; H A Averette
Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix.
Cancer 1996;77(8):1489-93.
1996: Manuel Penalver; G Barreau; BU Sevin; Hervy E Averette
Surgery for the treatment of locally recurrent disease.
Journal of the National Cancer Institute. Monographs 1996;(21):117-22.
1995: BU Sevin; Mehrdad Nadji; B Lampe; Y Lu; S Hilsenbeck; Ossi R Koechli; Hervy E Averette
Prognostic factors of early stage cervical cancer treated by radical hysterectomy.
Cancer 1995;76(10 Suppl):1978-86.
1995: MF Janicek; BU Sevin; H N Nguyen; Hervy E Averette
Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines.
Gynecologic oncology 1995;59(1):87-92.
1995: Edgar Petru; BU Sevin; Josef Haas; R Ramos; J Perras
A correlation of cell cycle perturbations with chemosensitivity in human ovarian cancer cells exposed to cytotoxic drugs in vitro.
Gynecologic oncology 1995;58(1):48-57.
1995: M Rodriguez; BU Sevin; J Perras; H N Nguyen; C Pham; A J Steren; Ossi R Koechli; Hervy E Averette
Paclitaxel: a radiation sensitizer of human cervical cancer cells.
Gynecologic oncology 1995;57(2):165-9.
1995: Ossi R Koechli; Gabriel N Schaer; BU Sevin; J P Perras; V Schenk; M Rodriguez; Michael Untch; A Steren; U Haller
In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.
Anti-cancer drugs 1995;6(1):94-100.
1994: Ossi R Koechli; BU Sevin; J P Perras; Roberto Angioli; Michael Untch; A Steren; C Ramachandran; Hervy E Averette
Comparative chemosensitivity profiles in three human breast cancer cell lines with the ATP-cell viability assay.
Oncology 1994;51(6):552-8.
1994: Michael Untch; BU Sevin; J P Perras; Roberto Angioli; A Untch; R D Hightower; Ossi R Koechli; Hervy E Averette
Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Gynecologic oncology 1994;53(1):44-9.
1994: M Rodriguez; H N Nguyen; Hervy E Averette; A J Steren; Manuel Penalver; T Harrison; BU Sevin
National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age.
Cancer 1994;73(4):1245-50.
1994: H N Nguyen; F Salman; D Donato; Hervy E Averette; BU Sevin; Manuel Penalver
Removal of indwelling ureteral catheters with ultrasound guidance.
The Journal of reproductive medicine 1994;39(2):92-6.
1994: Michael Untch; A Untch; BU Sevin; Roberto Angioli; J P Perras; Ossi R Koechli; Hervy E Averette
Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Anti-cancer drugs 1994;5(1):24-30.
1994: Ossi R Koechli; BU Sevin; J P Perras; Roberto Angioli; A Steren; M Rodriguez; Parvin Ganjei-Azar; Hervy E Averette
Growth characteristics of nonmalignant cells in the ATP cell viability assay.
Oncology 1994;51(1):35-41.
1994: BU Sevin; J P Perras; O R Köchli
Current status and future directions of chemosensitivity testing.
Contributions to gynecology and obstetrics 1994;19():179-94.
1994: O R Köchli; BU Sevin; Hervy E Averette; U Haller
Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer.
Contributions to gynecology and obstetrics 1994;19():12-23.
1994: O R Köchli; J P Perras; BU Sevin
ATP-cell viability assay methodology in both fresh gynecologic tumors and cell lines.
Contributions to gynecology and obstetrics 1994;19():108-21.
1994: BU Sevin
Multimodality therapy in gynecologic oncology.
Contributions to gynecology and obstetrics 1994;19():1-11.
1993: H N Nguyen; Hervy E Averette; W Hoskins; Manuel Penalver; BU Sevin; A Steren
National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival.
Cancer 1993;72(12):3663-70.
1993: H N Nguyen; Hervy E Averette; W Hoskins; BU Sevin; Manuel Penalver; A Steren
National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system.
Cancer 1993;72(10):3007-11.
1993: Ossi R Koechli; BU Sevin; J P Perras; T C Chou; Roberto Angioli; A Steren; Michael Untch; Hervy E Averette
Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay.
Breast cancer research and treatment 1993;28(1):21-7.
1993: T A Harrison; BU Sevin; Ossi R Koechli; H N Nguyen; Hervy E Averette; Manuel Penalver; D M Donato; Mehrdad Nadji
Adenosquamous carcinoma of the cervix: prognosis in early stage disease treated by radical hysterectomy.
Gynecologic oncology 1993;50(3):310-5.
1993: H N Nguyen; BU Sevin; Hervy E Averette; Parvin Ganjei-Azar; J Perras; R Ramos; Roberto Angioli; D Donato; Manuel Penalver
The role of DNA index as a prognostic factor in early cervical carcinoma.
Gynecologic oncology 1993;50(1):54-9.
1993: A Steren; BU Sevin; J Perras; R Ramos; Roberto Angioli; H Nguyen; Ossi R Koechli; Hervy E Averette
Taxol as a radiation sensitizer: a flow cytometric study.
Gynecologic oncology 1993;50(1):89-93.
1993: Roberto Angioli; BU Sevin; J P Perras; Michael Untch; Ossi R Koechli; H N Nguyen; A Steren; J G Schwade; C Villani; Hervy E Averette
In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines.
Cancer 1993;71(11):3717-25.
1993: Roberto Angioli; Michael Untch; BU Sevin; A Steren; R D Hightower; J P Perras; H N Nguyen; Ossi R Koechli; Hervy E Averette
Enhancement of progesterone receptor levels by interferons in AE-7 endometrial cancer cells.
Cancer 1993;71(9):2776-81.
1993: H N Nguyen; BU Sevin; Hervy E Averette; R Ramos; Parvin Ganjei-Azar; J Perras
Evidence of tumor heterogeneity in cervical cancers and lymph node metastases as determined by flow cytometry.
Cancer 1993;71(8):2543-50.
1993: A Steren; H N Nguyen; Hervy E Averette; RE Estape; Roberto Angioli; D M Donato; Manuel Penalver; BU Sevin
Radical hysterectomy for stage IB adenocarcinoma of the cervix: the University of Miami experience.
Gynecologic oncology 1993;48(3):355-9.
1993: Manuel Penalver; D Bejany; D M Donato; BU Sevin; Hervy E Averette
Functional characteristics and follow-up of the continent ileal colonic urinary reservoir. Miami pouch.
Cancer 1993;71(4 Suppl):1667-72.
1993: BU Sevin; J P Perras; Hervy E Averette; D M Donato; Manuel Penalver
Chemosensitivity testing in ovarian cancer.
Cancer 1993;71(4 Suppl):1613-20.
1993: Hervy E Averette; H N Nguyen; D M Donato; Manuel Penalver; BU Sevin; RE Estape; W A Little
Radical hysterectomy for invasive cervical cancer. A 25-year prospective experience with the Miami technique.
Cancer 1993;71(4 Suppl):1422-37.
1993: A Steren; BU Sevin; J Perras; Roberto Angioli; H Nguyen; L Guerra; Ossi R Koechli; Hervy E Averette
Taxol sensitizes human ovarian cancer cells to radiation.
Gynecologic oncology 1993;48(2):252-8.
1993: J P Perras; R Ramos; BU Sevin
Demonstration of an S phase population of cells without DNA synthesis generated by cisplatin and pentoxifylline.
Cytometry 1993;14(4):441-8.
1993: R D Hightower; BU Sevin; J Perras; H Nguyen; Roberto Angioli; Michael Untch; Hervy E Averette
In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
Cancer investigation 1993;11(3):276-82.
1993: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; R Ramos; D Donato; K Ochiai; Manuel Penalver
Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines.
Cancer investigation 1993;11(3):264-75.
1993: H N Nguyen; BU Sevin; Hervy E Averette; C Gottlieb; J Perras; D Donato; Manuel Penalver
Radiosensitization of uterine cancer cell lines by cytotoxic agents.
Gynecologic oncology 1993;48(1):16-22.
1993: Michael Untch; BU Sevin; A Untch; Gottfried E Konecny; C Nestle-Krämling; M Korell; Hermann Hepp
[Testing chemosensitivity of cancer cell lines and gynecologic tumors with the ATP assay].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():311-3.
1992: R D Hightower; BU Sevin; J P Perras; Michael Untch; Roberto Angioli; R Ramos; Hervy E Averette
Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay.
Gynecologic oncology 1992;47(2):186-90.
1992: Michael Untch; BU Sevin; J P Perras; Roberto Angioli; A Baibl; H N Nguyen; R D Hightower; Hervy E Averette
Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Gynecologic oncology 1992;47(2):172-8.
1992: BU Sevin; Mehrdad Nadji; Hervy E Averette; S Hilsenbeck; D Smith; B Lampe
Microinvasive carcinoma of the cervix.
Cancer 1992;70(8):2121-8.
1992: H N Nguyen; BU Sevin; Hervy E Averette; C F Gottlieb; J Perras; R Ramos; D Donato; Manuel Penalver
The use of ATP bioluminescence assay and flow cytometry in predicting radiosensitivity of uterine cancer cell lines: correlation of radiotoxicity and cell cycle kinetics.
Gynecologic oncology 1992;46(1):88-96.
1992: H N Nguyen; BU Sevin; Hervy E Averette; W Voigt; J Perras; Roberto Angioli; R Ramos; D Donato; Manuel Penalver
Determination of hormonal response in uterine cancer cell lines by the ATP bioluminescence assay and flow cytometry.
Gynecologic oncology 1992;46(1):55-61.
1992: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; D Donato; Manuel Penalver
The use of ATP bioluminescence assays in selecting a drug screen panel for chemosensitivity testing of uterine cancer cell lines.
Gynecologic oncology 1992;45(2):185-91.
1992: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; Michael Untch; R Ramos; D Donato; Manuel Penalver
Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines.
Gynecologic oncology 1992;45(2):164-73.
1992: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; R Ramos; D Donato
Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.
Journal of cancer research and clinical oncology 1992;118(7):515-22.
1992: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; R Hightower; R Ramos; D Donato; Manuel Penalver
In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.
Cancer chemotherapy and pharmacology 1992;30(1):37-42.
1992: Roberto Angioli; BU Sevin; J P Perras; Michael Untch; R D Hightower; H N Nguyen; A Steren; C Villani; Hervy E Averette
Rationale of combining radiation and interferon for the treatment of cervical cancer.
Oncology 1992;49(6):445-9.
1991: M A Schiano; BU Sevin; J Perras; R Ramos; E H Wolloch; Hervy E Averette
In vitro enhancement of cis-platinum antitumor activity by caffeine and pentoxifylline in a human ovarian cell line.
Gynecologic oncology 1991;43(1):37-45.
1991: E H Wolloch; BU Sevin; J P Perras; C F Gottlieb; Alan Pollack; R Ramos; M A Schiano; Hervy E Averette
Cell kinetic perturbations after irradiation and caffeine in the BG-1 ovarian carcinoma cell line.
Gynecologic oncology 1991;43(1):29-36.
1991: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; D Donato; Manuel Penalver
Comparative evaluation of single and combination chemotherapy in uterine cancer cell lines.
Gynecologic oncology 1991;42(3):227-32.
1991: Robert Gerhardt; J P Perras; BU Sevin; Edgar Petru; R Ramos; L Guerra; Hervy E Averette
Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
American journal of obstetrics and gynecology 1991;165(2):245-55.
1991: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; R Ramos; Manuel Penalver; D Donato
The effects of Provera on chemotherapy of uterine cancer cell lines.
Gynecologic oncology 1991;42(2):165-77.
1991: BU Sevin; R Ramos; Robert Gerhardt; L Guerra; S Hilsenbeck; Hervy E Averette
Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study.
Obstetrics and gynecology 1991;77(5):729-34.
1991: Edgar Petru; BU Sevin; Hervy E Averette; Ossi R Koechli; S Hilsenbeck
Long-term survival in stage III and IV ovarian cancer.
Archives of gynecology and obstetrics 1991;249(2):87-93.
1990: G M Boike; Edgar Petru; BU Sevin; Hervy E Averette; T C Chou; Manuel Penalver; D Donato; M Schiano; S G Hilsenbeck; J Perras
Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line.
Gynecologic oncology 1990;38(3):315-22.
1990: Edgar Petru; BU Sevin; Hervy E Averette; Ossi R Koechli; J P Perras; S Hilsenbeck
Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer.
Gynecologic oncology 1990;38(2):181-6.
1990: Edgar Petru; BU Sevin; J Perras; G Boike; R Ramos; H Nguyen; Hervy E Averette
Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence.
Gynecologic oncology 1990;38(2):155-60.
1990: Edgar Petru; G Boike; BU Sevin
Potentiation of cisplatin cytotoxicity by methylxanthines in vitro.
Journal of cancer research and clinical oncology 1990;116(5):431-3.
1989: Manuel Penalver; D E Bejany; Hervy E Averette; D M Donato; BU Sevin; G Suarez
Continent urinary diversion in gynecologic oncology.
Gynecologic oncology 1989;34(3):274-88.
1989: C R Harrison; Hervy E Averette; M A Jarrell; Manuel Penalver; D Donato; BU Sevin
Carcinoma of the fallopian tube: clinical management.
Gynecologic oncology 1989;32(3):357-9.
1989: R E Kingston; BU Sevin; R Ramos; M Saks; D Donato; M A Jarrell; Hervy E Averette
Synergistic effects of cis-platinum and cytosine arabinoside on ovarian carcinoma cell lines, demonstrated by dual-parameter flow cytometry.
Gynecologic oncology 1989;32(3):282-7.
1988: BU Sevin; Z L Peng; J P Perras; Parvin Ganjei-Azar; Manuel Penalver; Hervy E Averette
Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing.
Gynecologic oncology 1988;31(1):191-204.
1988: D Provencher; B Valme; Hervy E Averette; Parvin Ganjei-Azar; D Donato; Manuel Penalver; BU Sevin
HIV status and positive Papanicolaou screening: identification of a high-risk population.
Gynecologic oncology 1988;31(1):184-90.
1988: D Donato; M Jarrell; Hervy E Averette; Theodore I Malinin; BU Sevin; R Girtanner
Reconstructive techniques in gynecologic oncology: the use of human dura mater allografts.
European journal of gynaecological oncology 1988;9(2):135-9.
1987: Hervy E Averette; D M Donato; J L Lovecchio; BU Sevin
Surgical staging of gynecologic malignancies.
Cancer 1987;60(8 Suppl):2010-20.
1987: Manuel Penalver; Hervy E Averette; BU Sevin; M Lichtinger; R Girtanner
Gastrointestinal surgery in gynecologic oncology: evaluation of surgical techniques.
Gynecologic oncology 1987;28(1):74-82.
1986: M Lichtinger; Hervy E Averette; Manuel Penalver; BU Sevin
Major surgical procedures for gynecologic malignancy in elderly women.
Southern medical journal 1986;79(12):1506-10.
1986: M Lichtinger; BU Sevin; L Dembicki; Hervy E Averette
[Pelvic exenteration].
Der Gynäkologe 1986;19(2):81-5.
1986: M Lichtinger; Hervy E Averette; R Girtanner; BU Sevin; Manuel Penalver
Small bowel complications after supravesical urinary diversion in pelvic exenteration.
Gynecologic oncology 1986;24(2):137-42.
1984: BU Sevin; R Ramos; M Lichtinger; R E Girtanner; Hervy E Averette
Antibiotic prevention of infections complicating radical abdominal hysterectomy.
Obstetrics and gynecology 1984;64(4):539-45.
1984: Hervy E Averette; M Lichtinger; BU Sevin; R E Girtanner
Pelvic exenteration: a 15-year experience in a general metropolitan hospital.
American journal of obstetrics and gynecology 1984;150(2):179-84.